ASND
Ascendis Pharma AS
228.00$
+0.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.2% | 30.9% | -131.6% | -535.4% | -1,306.5% | -6,215.6% | -1,311.8% | -1,315.4% | -3,905.5% | -5,369.6% | -968.7% | -175.2% | -84.2% | 7.5% | |
| 2.7% | 2.0% | 3.6% | 6.9% | 14.7% | 48.0% | 8.3% | 50.0% | 135.9% | 197.9% | 35.1% | 7.1% | 4.9% | 2.5% | |
| 0.8% | 3.3% | 9.1% | 21.1% | 158.9% | 634.6% | 185.7% | 280.3% | 764.7% | 859.2% | 125.4% | 25.0% | 26.3% | 16.8% | |
| – | 6.4% | -16.0% | -101.7% | 77.8% | 1,506.1% | -106.7% | 234.2% | 1,998.0% | -7.1% | 172.3% | – | – | – | |
| -15.7% | 2.6% | -53.0% | -57.4% | 88.3% | 328.1% | 16.1% | 30.4% | -13.9% | -628.9% | -24.4% | -37.4% | -29.5% | 9.9% | |
| 1.9% | 5.9% | 2.9% | 12.8% | 14.6% | 61.5% | 25.0% | 38.6% | 310.0% | 311.6% | 28.3% | 0.9% | 0.4% | 1.2% | |
| -1.9% | -5.9% | -2.9% | -12.8% | -14.6% | -61.5% | -25.0% | -38.6% | -4,188.1% | -1,421.7% | 120.6% | 107.4% | 1.9% | -1.2% | |
| – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | 426.1% | 9.9% | – | – | – | |
| – | 559.3% | 987.5% | 1,406.0% | 2,734.8% | 8,699.9% | 2,045.0% | 3,957.6% | 0.0% | -277.8% | -205.8% | -0.7% | 0.0% | -2.4% | |
| – | -1.1% | 0.0% | 0.0% | -87.7% | -263.9% | -38.2% | -30.2% | -68.7% | -82.7% | 971.0% | 47.2% | 33.8% | -3.2% | |
| -1.3% | -1.1% | 342.6% | 1,302.6% | 2,550.2% | 8,151.7% | 1,921.1% | 3,690.4% | 8,667.5% | 4,517.7% | 775.3% | 50.3% | 122.1% | 5.0% | |
| -7.4% | 24.0% | 219.8% | 855.9% | 1,317.4% | 981.8% | 779.8% | 2,394.3% | -195.4% | -1,777.4% | -2.9% | -19.7% | 46.0% | 17.7% | |
| -6.1% | 25.1% | -134.5% | -548.2% | -1,321.1% | -6,277.1% | -1,336.8% | -1,354.0% | -4,215.4% | -5,681.2% | -997.0% | -176.1% | -84.6% | 6.3% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.